Moderna, Inc. (MRNA) Stock Price & How to Invest

Last updated November 2026

Short answer

Moderna (MRNA) is a large-cap mRNA biotech whose story has turned from a post-COVID turnaround into a cancer-vaccine bet: COVID revenue has collapsed from its 2021-2022 peak, but positive Phase 3 results in August 2026 for the Merck-partnered personalized melanoma vaccine sent the stock up roughly 590% in 2026, to about $213 and an ~$85 billion market value as of October 16. It trades like an option on that pipeline rather than on current earnings, which are still deeply negative.

MRNA stock price

As of 2026-11-16, Moderna, Inc. (MRNA) last closed at $215.27, up 769.4% over the past year. Over the past 52 weeks it has traded between $22.36 and $269.00.

MRNA last close
$215.27
1 day
-3.63%
1 month
-1.26%
1 year
+769.43%
52-week range
$22.36 to $269.00
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Moderna, Inc.'s investor relations page. Walnut is informational, not investment advice.

MRNA key stats

At $215.27 on November 16, 2026, Moderna, Inc. (MRNA) has a market cap of $87.1B.

Market cap
$87.1B
Price to book
12.7
Beta
1.17

Market cap, P/E and yield are measured at the $215.27 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Moderna, Inc. (MRNA)?

The last two weeks for Moderna, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • MRNA closed at $215.27 on November 16, 2026, down 20.0% over the past five trading days (from $269.00).
  • On November 16, 2026, Moderna, Inc. filed an 8-K with the SEC reporting a material agreement and new debt or another financial obligation (Item 1.01, Item 2.03). Read the 8-K on sec.gov
  • On November 13, 2026, Moderna, Inc. filed an 8-K with the SEC reporting a change in its directors or officers (Item 5.02). Read the 8-K on sec.gov
  • On November 6, 2026, Moderna, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 6, 2026, Moderna, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 9, 2026, Goldman Sachs raised its target to $195.00 from $137.00 (Neutral).
  • On November 9, 2026, Piper Sandler raised its target to $305.00 from $230.00 (Overweight).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Moderna, Inc. (MRNA) latest quarter

Moderna reported revenue of $1.3 billion for Q3 2026, up 29% from a year earlier (Moderna, Nov 6, 2026).

Revenue
$1.3 billion
up 29% from a year earlier
Diluted EPS
$0.38
n/a
COVID (Spikevax and mNEXSPIKE)
$1.2 billion
up 28% from a year earlier

Source: Moderna Q3 2026 results, Nov 6, 2026. Full earnings breakdown

What does Moderna, Inc. (MRNA) do?

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.

The investment picture is a classic biotech turnaround. Q1 2026 revenue was about $389 million and the company posted a net loss of about $1.34 billion (heavily inflated by an ~$878 million legal settlement charge). Q2 2026 revenue fell to about $145 million with a net loss of about $782 million, though the loss per share of $1.97 was slightly better than the $2.06 consensus. Trailing revenue is about $2.2 billion against a trailing net loss of about $3.2 billion. Management guides to up to 10% revenue growth in 2026 and a cash flow break-even target by 2028, backed by a multibillion-dollar cash cushion. That leaves MRNA valued far more on future pipeline outcomes than on trailing financials, and 2026 showed how violently that can work. In August, Moderna and Merck announced Phase 3 success for intismeran autogene in melanoma, and the shares, which had bottomed near $22 in 2025, climbed to a 52-week high of about $242. As of October 16, 2026 the stock closed near $213.12, up about 590% year to date and about 685% over one year, after a roughly 9% one-day drop that Friday as investors took profits. Detailed Phase 3 results are expected at a medical meeting later in October, and Q3 2026 results are scheduled for November 6.

What's driving Moderna, Inc. (MRNA)?

1. Respiratory franchise beyond COVID

Moderna is trying to convert a single-product COVID business into a broader respiratory portfolio. mRESVIA (RSV) is already approved for older adults, and Europe cleared mNEXSPIKE plus the mCOMBRIAX combination shot. A U.S. flu decision (mRNA-1010) was scheduled around August 2026 after an earlier Refusal-to-File setback, and respiratory sales remain small and seasonal: Q2 2026 revenue was only about $145 million, with consensus near $892 million for the fall-season Q3.

2. Oncology optionality via Merck partnership

Intismeran autogene (mRNA-4157), the personalized cancer vaccine developed with Merck, is the highest-upside pipeline bet. Five-year Phase 2b adjuvant melanoma data showed a roughly 49% reduction in recurrence or death when combined with Keytruda versus Keytruda alone, and in August 2026 Moderna and Merck announced that the melanoma Phase 3 trial succeeded, the event behind the stock's 2026 surge. Detailed results are expected at a medical meeting later in October 2026, and additional Phase 3 trials span lung, bladder, and kidney cancers.

3. Cost discipline and a path to break-even

Management has framed 2026 around disciplined spending, targeting cash flow break-even by 2028 while preserving a large cash balance (about $5.1 billion of cash against about $1.3 billion of debt at mid-2026). International sales, including a U.K. government partnership, made up the bulk of recent revenue, which management points to as evidence of a more diversified base.

4. Platform leverage across many programs

Moderna carries one of the largest clinical-stage mRNA pipelines (dozens of candidates), spanning respiratory, latent viruses, rare diseases, and oncology. The thesis is that a single validated platform can produce multiple shots on goal, so a few approvals could re-rate the business even if individual programs fail.

What are the risks to Moderna, Inc. (MRNA)?

Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. The company is loss-making and burning cash, making it dependent on pipeline approvals landing on schedule. Regulatory risk is concrete: the FDA issued a Refusal-to-File letter for the flu vaccine earlier in 2026, and shifting U.S. vaccine policy adds uncertainty. Large legal settlements (such as the Arbutus and Genevant charge) can swing reported results, and much of the long-term value depends on the Merck-partnered cancer vaccine succeeding in Phase 3, which is far from guaranteed. Valuation risk is now acute: at about $85 billion the company trades near 38 times trailing sales, analysts are split (Goldman Sachs raised its target to $137 with a Neutral rating, Morgan Stanley is at $95, Citi has a Sell and an $80 target, all below the October 16 price), and the stock fell about 9% in a single day on October 16 as profit-taking set in. A disappointing detailed readout of the melanoma data could reverse much of the gain. Walnut is not an investment adviser.

What is the Moderna, Inc. (MRNA) forecast?

19 analysts publish price targets on MRNA, averaging $154.47 as of November 2026, or -28.2% against the $215.27 share price on November 16, 2026. The published targets run from $45.00 to $270.00, a wide spread, and the ratings split 4 buy, 16 hold, 3 sell. Over the last six months there have been 10 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MRNA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is MRNA a buy or a sell?

We give no verdict on Moderna, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Respiratory franchise beyond COVID. Moderna is trying to convert a single-product COVID business into a broader respiratory portfolio. The most optimistic published target, $270.00, assumes this works close to its best case.

The case against. Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. The most pessimistic target, $45.00, is roughly what MRNA is worth if this bites instead.

Read the full bull and bear case on MRNA, including what would have to change to break either one. Walnut is not an investment adviser.

Has Moderna, Inc. (MRNA) split its stock?

No. Moderna, Inc. (MRNA) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Moderna, Inc. (MRNA) valued?

Market cap, P/E and dividend yield at today's price are in the MRNA key stats above. The business figures below come from Moderna, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$2.2 billion
  • Q2 2026 revenue: ~$145 million
  • Net income (TTM): ~-$3.2 billion
  • Q2 2026 EPS: -$1.97 vs -$2.06 consensus
  • Cash vs debt: ~$5.1 billion cash, ~$1.3 billion debt
  • Break-even target: cash flow break-even by ~2028

As of October 2026: MRNA trades on pipeline potential rather than current earnings: it is loss-making, revenue is far below its pandemic peak, and P/E is not meaningful. What changed in 2026 is the price of that option, with the stock up about 590% year to date to roughly 38 times trailing sales after the August Phase 3 melanoma success. The 18 analysts Yahoo Finance tracks have a mean target near $124, well under the $213 close, so the detailed data later in October and the November 6 Q3 report (consensus revenue near $892 million, EPS near -$1.30) carry unusual weight.

Which ETFs hold Moderna, Inc. (MRNA)?

If you want MRNA exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in MRNAExpense ratio
RSPInvesco S&P 500 Equal Weight ETF0.29%0.20%
VBVanguard Morningstar Small-Cap ETF0.62%0.03%
BBHVanEck Biotech ETF6.4%0.35%
IBBiShares Biotechnology ETF4.94%0.44%
IWRiShares Russell Mid-Cap ETF0.53%0.19%
XBIState Street SPDR S&P Biotech ETF2.0%0.35%
VBRVanguard Morningstar Small-Cap Value ETF1.1%0.05%
IWSiShares Russell Mid-Cap Value ETF0.71%0.23%

What themes does Moderna, Inc. (MRNA) fit?

These are the investment theses MRNA naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Who competes with Moderna, Inc. (MRNA)?

Direct mRNA rivals

Pfizer with its partner BioNTech is Moderna's closest peer, competing head-to-head in COVID and flu vaccines and, increasingly, in mRNA-based oncology. Together with Moderna, these players dominate clinical-stage mRNA development, so pricing, approvals, and head-to-head efficacy data directly affect Moderna's share.

Vaccine and pharma incumbents

Large vaccine makers such as GSK, Sanofi, and Novavax compete in respiratory vaccines (flu, RSV, and COVID) using more established non-mRNA platforms, while Merck is both a partner (on the cancer vaccine) and a broad oncology competitor. These incumbents have deeper commercial infrastructure and diversified revenue that Moderna lacks.

Emerging mRNA and biotech platforms

Smaller mRNA and biotech companies (for example CureVac and other platform startups) and the wider immuno-oncology field compete for the same pipeline opportunities in personalized cancer vaccines and rare diseases. They are less commercially significant today but shape long-run competitive and licensing dynamics.

What stocks are similar to Moderna, Inc. (MRNA)?

Other names that sit close to MRNA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Moderna, Inc. (MRNA)

There are three common ways to get MRNA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (RSP, VB, BBH), which spreads the position across many companies. Or build it into a focused thematic portfolio, so MRNA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MRNA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Moderna, Inc. (MRNA)

MRNA is a post-COVID biotech whose value now sits almost entirely in a late-stage pipeline, led by a cancer vaccine that has cleared Phase 3, while the existing business shrinks and losses continue. After a roughly 590% run in 2026 the price assumes a great deal of that pipeline succeeds commercially.

More on Moderna, Inc. (MRNA)

Whether MRNA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MRNA a buy or a sell?, and where the stock could go from here in the MRNA stock forecast.

For income investors, whether MRNA pays a dividend and how the payout looks is covered in does MRNA pay a dividend? And to weigh MRNA against a peer, read the full side-by-side comparisons: MRNA vs VRTX and MRNA vs REGN.

Wondering how MRNA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Moderna, Inc.

Ask Walnut's AI anything about MRNA and see how it fits what you own.

FAQ

What does Moderna do?

+

Moderna is a biotechnology company that develops vaccines and therapeutics based on messenger RNA (mRNA). It is best known for its Spikevax COVID-19 vaccine and is now expanding into RSV, flu, combination respiratory shots, and cancer vaccines.

Is Moderna profitable?

+

No. As of October 2026 Moderna is loss-making, with a trailing net loss of about $3.2 billion, including a Q1 2026 loss worsened by a large legal settlement charge and a Q2 2026 loss of about $782 million. Management is targeting cash flow break-even by around 2028 through revenue growth and cost cuts.

How much revenue does Moderna make now?

+

Revenue has fallen sharply from its pandemic peak. Q1 2026 revenue was about $389 million and Q2 about $145 million, for trailing revenue of about $2.2 billion. Management guided to up to roughly 10% revenue growth for 2026, with a large share coming from international markets; sales are heavily weighted to the fall respiratory season.

What is Moderna's most important pipeline product?

+

Two stand out: intismeran autogene (mRNA-4157), the personalized cancer vaccine developed with Merck, which met its goal in a Phase 3 melanoma trial announced in August 2026, and the mRNA-1010 seasonal flu vaccine, which had a U.S. regulatory decision scheduled around August 2026 after an earlier setback.

Why is MRNA stock so volatile?

+

Because the company's value depends heavily on pipeline outcomes rather than current earnings. Clinical trial results, FDA and EU regulatory decisions, and shifts in vaccine policy can each move the stock significantly. 2026 is the extreme example: the stock rose from about $31 at the start of the year to a high near $242 after the August cancer-vaccine news, then fell about 9% in one day on October 16.

Who are Moderna's main competitors?

+

Its closest rival is Pfizer with BioNTech in mRNA vaccines and oncology. It also competes with vaccine incumbents like GSK, Sanofi, and Novavax in respiratory vaccines, plus smaller mRNA platforms and the broader immuno-oncology field.

Does Moderna pay a dividend?

+

Moderna does not pay a dividend as of October 2026. It is a loss-making biotech reinvesting its cash into research, development, and its pipeline rather than returning cash to shareholders.

What are the biggest risks for Moderna?

+

The main risks are declining COVID demand, ongoing losses and cash burn, regulatory setbacks (such as the FDA Refusal-to-File letter for its flu vaccine), uncertain U.S. vaccine policy, and reliance on pipeline programs, especially the Merck cancer vaccine, succeeding in late-stage trials.

Why did Moderna stock rise so much in 2026?

+

Mainly because of the cancer vaccine. In August 2026 Moderna and Merck announced Phase 3 success for intismeran autogene in melanoma, and investors began valuing Moderna on oncology rather than its shrinking COVID business. As of October 16, 2026 the stock closed near $213.12, up about 590% year to date and about 685% over one year, versus a 2025 low near $22.

How did Moderna do in its latest quarter?

+

In Q2 2026 Moderna reported revenue of about $145 million and a net loss of about $782 million, or $1.97 per share, slightly better than the $2.06 loss analysts expected. Cash was about $5.1 billion at quarter end. Q3 2026 results are due November 6, with consensus near $892 million of revenue and a loss of about $1.30 per share.

Guides that feature MRNA

MRNA is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Moderna, Inc.'s investor relations page or your broker before making investment decisions.